Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists.

Παρόμοια τεκμήρια

• The ROSI study (risedronate in adults with osteogenesis imperfecta type 1)
  ανά: Duncan, E, κ.ά.
  Έκδοση: (2005)
• The ROSI study (Risedronate in adults with osteogenesis imperfecta type 1): Improved BMD but high fracture rate persists.
  ανά: Bradbury, L, κ.ά.
  Έκδοση: (2006)
• Application of Orthopantomography in the Analysis of Bone Mineral Density in Patients with Osteogenesis Imperfecta
  ανά: Lara García-Boedo, κ.ά.
  Έκδοση: (2024-02-01)
• Changes of bone turnover markers and bone mineral density among postmenopausal Thai women with osteoporosis receiving generic risedronate
  ανά: Ammarin Suwan, κ.ά.
  Έκδοση: (2024-10-01)
• The Effects of Risedronate Therapy Combined With Vitamin D and Calcium on Biochemical Markers of Bone Turnover and Bone Mineral Density in Postmenopausal Osteoporosis
  ανά: Hüsniye Koç, κ.ά.
  Έκδοση: (2004-12-01)